β Home
βΉοΈ Info
π§Ύ At a Glance π Core Facts ποΈ Products/Services β Ratings π§βπΌ Executives π¬ My Commentsπ‘ Analytics
π Insights (3) π’ Company Q&A (663) π οΈ Industry Q&A (164) π Competitors π Price Low π Price Swings β‘ SWOT ποΈ PEST π Porter's Five Forces β¨ Score Positive β οΈ Risk Assessment π§© Segmentation π Ά Google Linksπ Ratios
π° Margins π Financial Ratios π± Growth π Enterprise Value π Key Metrics π΅ Dividendsπ§ Tools
β Due Diligenceπ₯ Video Insights
Equasens has suffered a dramatic share-price decline, but its business performance tells a more interesting story. On November 20, 2026, shares closed at β¬26.25, approximately 42% below their 2026 high of β¬45.35. The market appears concerned about slowing organic growth despite improving profitability. The financial results are encouraging. First-half 2026 revenue increased 7.3% to β¬124.5 million, while net profit rose 10.5% to β¬20 million. The operating margin improved from 18.2% to 19%, and the EBITDA margin reached 26.8%. Net cash increased to β¬93.2 million. However, nine-month revenue growth slowed to 5.6%, with organic growth of only 0.9%. Third-quarter organic revenue actually declined 0.2%. Acquisitions are supporting reported growth, while management is investing in artificial intelligence, cloud healthcare infrastructure and new digital services. The dividend increased from β¬1.25 per share in 2024 to β¬1.40 in 2025. At the current price, the latest annual dividend represents a yield of approximately 5.3%. For value investors, strong margins, cash reserves and a lower valuation are attractive. The main risks are weak organic growth, acquisition integration and competitive pressure. A recovery depends on renewed organic expansion. This review is for informational and educational purposes only, not financial advice.
Equasens has slipped to around β¬30.10, close to its 52 week low of β¬30.00 and roughly 35% below the recent high of β¬46.70. The timing is particularly interesting because the company still reports solid underlying growth. In 2025, revenue increased 9.1% to β¬236.5 million, while net profit rose 8.8% to β¬41.1 million. The operating margin remained above 20%, and net cash reached β¬83.6 million. Recurring revenue also grew 8.8%, providing an important source of visibility. The first quarter of 2026 brought another 7.7% increase in reported revenue to β¬61.4 million, although organic growth was more modest at 2.9%. The company has continued investing in acquisitions and technology, including its Erevo acquisition. The dividend is another attraction: β¬1.40 was approved for 2025, up from β¬1.25 for 2024. At β¬30.10, that represents a yield of about 4.7%. The immediate concern is a September fire that destroyed an ASCA facility and inventory. Equasens expects disruption to last about four weeks, although backup stock and its continuity plan should limit the impact. Recovery could depend on continued growth and successful integration. Risks include slower organic expansion, acquisition execution and temporary disruption. This review is for informational and educational purposes only, not financial advice.
Is Equasens an undervalued healthcare technology company or a value trap? In this video, we examine its business model, financial performance, dividend growth, recent developments, key risks, and the reasons behind its depressed share price. Discover why this French healthcare software company is attracting the attention of value investors. Visit InsightfulValue.com for more in-depth company analysis, and donΒ΄t forget to subscribe, like the video, leave a comment, and join our newsletter through the link below.
